Background: While music-based therapy (MBT) has been shown to improve motor and non-motor features in multiple sclerosis (MS), benefits of tango have never been assessed.
Objective: To evaluate the benefits of tango classes on quality of life (QoL), mood, fatigue, gait, balance, perception of cognitive disorder and sexuality in people with MS.
Methods: 7 participants (age 41.14 ± 14.27 years, disease duration 14.14 ± 7.6 years) and respective partners undertook one-hour weekly classes for 20 weeks. Participants had early-stage MS (EDSS<3.5). They were assessed for mood (ZUNG rating scale; Beck Depression Inventory -II); balance (Berg Balance Test; Tinetti scale), cognition (MS Neuropsychological Screening Questionnaire), SD (Multiple Sclerosis Intimacy and Sexuality Questionnaire), fatigue (Fatigue Severity Scale) and QoL (36-Item Short Form Survey).
Results: Group comparison of pre-post change scores showed a general improvement in all the outcome measures, which was significant in mood, SD, cognition and QoL.
Discussions And Conclusion: Tango classes provides benefits to pwMS, especially on non-motor symptoms. Follow-up assessment is required to confirm the durability of these effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clineuro.2024.108380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2). Here, we report results from cohort 1 of this clinical trial.
View Article and Find Full Text PDFBayesian Latent Class Models for Evaluating the Validity of Claim-based Definitions of Disease Outcomes.
Ann Clin Epidemiol
October 2024
Center of Medical Statistics, Minato-Ku, Tokyo, Japan.
Background: Large electronic databases have been widely used in recent years; however, they can be susceptible to bias due to incomplete information. To address this, validation studies have been conducted to assess the accuracy of disease diagnoses defined in databases. However, such studies may be constrained by potential misclassification in references and the interdependence between diagnoses from the same data source.
View Article and Find Full Text PDFFirst-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.
Clin Cancer Res
December 2024
Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- - The study aimed to assess the safety and pharmacological effects of BAY 2666605, a new drug designed to trigger a response in cancer cells by promoting the interaction of two proteins, PDE3A and SLFN12.
- - In a first-in-human trial, five patients with specific tumor characteristics received the drug, but the most notable adverse effect was severe thrombocytopenia (low platelet count), affecting three patients, leading to challenges in determining a safe dosage.
- - Ultimately, due to the severe side effects and the lack of positive treatment responses, the trial was halted, as the drug could not establish a therapeutic dose without causing significant safety issues.
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Oncologist
December 2024
Department of Medicine (Medical Oncology), Yale University, New Haven, CT 06510, United States.
Introduction: Approximately 20% of patients living with colorectal cancer (CRC) have activating mutations in their tumors in the PIK3CA oncogene. Two or more activating mutations (multi-hit) for the PIK3CA allele increase PI3K⍺ signaling compared to single-point mutations, resulting in exceptional response to PI3K⍺ inhibition. We aimed to identify the prevalence of PIK3CA multi-hit mutations in metastatic CRC to identify patients who may benefit from PI3K inhibitors.
View Article and Find Full Text PDFTargeting the multifaceted BRAF in cancer: New directions.
Oncotarget
July 2024
Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA.
Activating mutations in the mitogen-activated protein kinase (MAPK) pathway represent driver alterations governing tumorigenesis, metastasis, and therapy resistance. MAPK activation predominantly occurs through genomic alterations in and . BRAF is an effector kinase that functions downstream of and propagates this oncogenic activity through MEK and ERK.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!